Want to see CTEV full AI Analyst Report?
Top Page
Claritev
(NYSE:CTEV)
Select Model
Select Model
Rating:55Neutral
Price Target:
$33.00
▲(52.71% Upside)
Action:Reiterated
Date:08/09/26
The score is held back primarily by weak financial quality (negative equity, high debt, and continuing net losses despite improved operations). Offsetting factors include a constructive price trend and a strong, guidance-raising earnings call with accelerating bookings and pipeline momentum. Valuation remains constrained by losses (negative P/E) and no stated dividend support.
Positive Factors
Bookings momentum and large pipeline
Sustained ACV bookings growth and a >$300M pipeline with >3x coverage provide a durable revenue lead indicator. With management noting typical 2–4 quarter first-dollar conversion and further annualization, this supports multi-quarter revenue compounding, larger deal sizes, and predictable future cash conversion.
Negative Factors
High leverage and negative equity
Material leverage and negative shareholder equity directly constrain financial flexibility. This capital-structure impairment increases refinancing risk, elevates interest burden, and limits the company's ability to invest or absorb shocks, making durable operational gains harder to translate into balance-sheet repair.
Read all positive and negative factors
Positive Factors
Negative Factors
Bookings momentum and large pipeline
Sustained ACV bookings growth and a >$300M pipeline with >3x coverage provide a durable revenue lead indicator. With management noting typical 2–4 quarter first-dollar conversion and further annualization, this supports multi-quarter revenue compounding, larger deal sizes, and predictable future cash conversion.
Read all positive factors
Claritev (CTEV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$387.16M
Dividend YieldN/A
Average Volume (3M)120.62K
Price to Earnings (P/E)―
Beta (1Y)2.17
Revenue Growth5.53%
EPS Growth76.25%
CountryUS
Employees3,000
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-17.00
Shares Outstanding17,047,789
10 Day Avg. Volume124,087
30 Day Avg. Volume120,620
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-4.04
Price to Sales (P/S)0.73
P/FCF Ratio-57.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.50Price Target Upside92.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-15.93
Revenue Forecast (FY)$993.39M
Claritev Business Overview & Revenue Model
Company Description
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United Stat...
How the Company Makes Money
null...
Claritev Earnings Call Summary
Earnings Call Date:Aug 07, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: multi-quarter revenue growth, record/near-record EBITDA and cash flow, significant bookings acceleration and a substantially enlarged pipeline. Management raised revenue and EBITDA guidance and highlighted successful execution across TPA, Claims Intelligence and AI-enabled initiatives. Offsetting considerations include timing and mix-driven pressure on revenue per claim, network comparables impacted by prior-year one-time items, a near-term Payments timing miss, and some volume/regulatory uncertainty that introduces short-term variability. Overall, the positive metrics and trajectory substantially outweigh the manageable timing and mix headwinds.Positive Updates
Revenue Growth and Record Quarter
Total revenue $257.5M in Q2, up 6.6% year-over-year — fifth straight quarter of YoY growth and the highest revenue quarter in 15 quarters (since Q3 2022).
Negative Updates
Network Revenue Impacted by Prior-Year One-Time Items
Network revenue would have been positive YoY excluding a prior-year one-time amount (Q2 last year $5.4M referenced; company also cited ~$18.5M of one-time revenue affecting full-year comparables). Management expects network to be down high single digits on a full-year comparable basis due to these prior-year items.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Record Quarter
Total revenue $257.5M in Q2, up 6.6% year-over-year — fifth straight quarter of YoY growth and the highest revenue quarter in 15 quarters (since Q3 2022).
Read all positive updates
Company Guidance
Claritev raised its full‑year revenue guidance to $1.00–$1.02 billion (4%–6% growth, a two‑percentage‑point increase) and asked investors to model Q3 revenue flat with Q2, raised full‑year adjusted EBITDA guidance to $610–$620 million (≈61% margin), left capital spending unchanged at $160–$170 million, and increased free cash flow guidance by $5 million to $5–$15 million; management expects adjusted cash conversion to normalize to >50% by year‑end, reiterated that new ACV bookings typically convert to first revenue in ~2–4 quarters and fully annualize after another ~4 quarters, reaffirmed a target of at least 50% ACV bookings growth for 2026 (Q2 ACV was $30M, H1 ACV ~$74M with a $100M full‑year stretch goal), highlighted a >$300M active pipeline with >3x coverage, and reminded listeners of the near‑term cash seasonality (Q1 and Q3 generally consume cash; Q2–Q4 generate cash).Claritev Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
18
Very Negative
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 994.67M | 965.41M | 930.62M | 961.52M | 1.08B | 1.12B |
| Gross Profit | 352.42M | 266.58M | 691.22M | 726.06M | 875.62M | 942.31M |
| EBITDA | 338.80M | 475.44M | -1.01B | 651.93M | 158.32M | 814.99M |
| Net Income | -283.11M | -284.28M | -1.65B | -91.70M | -572.91M | 102.08M |
Balance Sheet | ||||||
| Total Assets | 4.76B | 4.89B | 5.15B | 6.96B | 7.37B | 8.22B |
| Cash, Cash Equivalents and Short-Term Investments | 14.37M | 16.81M | 16.85M | 71.55M | 334.05M | 185.33M |
| Total Debt | 4.62B | 4.63B | 4.54B | 4.57B | 4.78B | 4.93B |
| Total Liabilities | 5.05B | 5.06B | 5.07B | 5.26B | 5.58B | 5.88B |
| Stockholders Equity | -294.56M | -173.90M | 84.02M | 1.71B | 1.79B | 2.34B |
Cash Flow | ||||||
| Free Cash Flow | -17.92M | -12.28M | -10.51M | 62.87M | 282.63M | 320.10M |
| Operating Cash Flow | 133.03M | 117.32M | 107.62M | 171.72M | 372.36M | 404.69M |
| Investing Cash Flow | -142.38M | -121.02M | -118.12M | -249.79M | -104.45M | -228.38M |
| Financing Cash Flow | -30.27M | 2.36M | -41.31M | -180.99M | -115.74M | -114.68M |
Claritev Technical Analysis
Positive
21.61
Price Trends
28.64
Positive
24.46
Positive
30.70
Positive
Market Momentum
-0.49
Negative
64.55
Neutral
80.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Positive. The current price of 21.61 is below the 20-day moving average (MA) of 26.39, below the 50-day MA of 28.64, and below the 200-day MA of 30.70, indicating a bullish trend. The MACD of -0.49 indicates Negative momentum. The RSI at 64.55 is Neutral, neither overbought nor oversold. The STOCH value of 80.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTEV.
Claritev Risk Analysis
Claritev disclosed 62 risk factors in its most recent earnings report. Claritev reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Claritev Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $663.24M | 70.50 | 2.79% | ― | 14.05% | ― | |
70 Outperform | $4.05B | 29.32 | 3.59% | ― | 19.23% | 44.44% | |
68 Neutral | $103.68M | 30.65 | 16.87% | ― | 10.34% | ― | |
60 Neutral | $154.44M | -0.56 | -129.70% | ― | -2.83% | -223.32% | |
55 Neutral | $387.16M | -1.31 | 139.56% | ― | 5.53% | 76.25% | |
52 Neutral | $347.57M | -0.66 | -99.16% | ― | -21.26% | -290.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CTEV
Claritev
32.59
-29.02
-47.10%
CCLD
CareCloud
2.63
0.07
2.73%
EVH
Evolent Health
3.95
-5.27
-57.16%
PHR
Phreesia
12.51
-14.62
-53.89%
HCAT
Health Catalyst
1.73
-0.97
-35.93%
WAY
Waystar Holding Corp.
24.23
-10.25
-29.73%
Claritev Corporate Events
Business Operations and StrategyLegal ProceedingsRegulatory Filings and Compliance
Claritev Cleared of Criminal Probe, Faces Civil Inquiry
Neutral
Jun 22, 2026
In August 2024, Claritev Corporation received a confidential grand jury subpoena from the U.S. Department of Justice Antitrust Division in connection with a health insurance investigation. On June 17, 2026, the Antitrust Division informed the comp...
Legal ProceedingsRegulatory Filings and Compliance
Claritev Addresses DOJ Antitrust Probe, Ensures Compliance
Negative
May 18, 2026
Claritev Corporation disclosed that it received a confidential grand jury subpoena from the U.S. Department of Justice’s Antitrust Division in August 2024 related to an investigation concerning health insurance. The company stated it has ful...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.